Retina/Vitreous News

A 65-year-old man presented to the retina service for a preoperative cataract surgery evaluation after being followed for years for presumed retinitis pigmentosa.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Carolyn Sasse of Astellas highlights the company’s ophthalmology pipeline.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Ramanath Bhandari, MD, FASRS, of RevOpsis Therapeutics discusses the development of RO-104 for the treatment of retinal disease.

The FDA approved the Vabysmo 6-mg single-dose prefilled syringe for the treatment of wet age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion, according to a Genentech press release.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Shankar Ramaswamy, MD, of Kriya Therapeutics highlights the company’s gene therapy programs for geographic atrophy and thyroid eye disease.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Reenie McCarthy of Stealth BioTherapeutics discusses a phase 3 clinical trial of elamipretide in dry age-related macular degeneration.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Arshad M. Khanani, MD, MA, FASRS, of Sierra Eye Associates in Nevada, presents 3-month data on AVD-104 for geographic atrophy.

The FDA approved FYB203/Ahzantive as a biosimilar to Eylea, according to a joint press release from Formycon and Klinge Biopharma.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Thomas Aaberg Jr., MD, of Neurotech Pharmaceuticals, discusses NT-501, an encapsulated cell therapy in development for macular telangiectasia type 2.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, David Kirn, MD, of 4D Molecular Therapeutics provides an update on two candidates for retinal diseases.